6.5. CEE STAKEHOLDER INTERVIEW METHODOLOGY

Plotting data from our trial analytics and myeloma incidence, four country clusters have been identified.

Figure 8: Countries selected for stakeholder interviews (Croatia, Macedonia and Poland)

1. **Strong prevalence and low number of clinical trial** rates due to myeloma and an absence or a low number of clinical trials.
2. **Medium prevalence and high number of clinical trials** due to myeloma and a high number of clinical trials.
3. **Soft belly medium:** low prevalence and mortality rate and low number of clinical trials.
4. **Low reported/recorded prevalence and lack of clinical trials.** Seemingly low clinical needs can explain the lack of infrastructure and health policies.



Countries selected for stakeholder interviews: Poland, Croatia and North Macedonia

Poland, Croatia and North Macedonia were selected for further investigation for several reasons: they each belong a different country cluster, thereby reflecting situations in terms of disease prevalence and conducted trials. Additionally, MPE has member organisations in those three countries, which facilitates further investigation. For each country, interviews with a haematologist, a contract research organisation representative, a health authority representative and a representative of a patient organisation were scheduled, except for Croatia where an interview with a representative of the Ministry of Health's Medicinal Products and Medical Device Department could not be held (see Table 24).

APPENDICES

Table 26: Interviewed stakeholders

	POLAND	CROATIA	NORTH MACEDONIA
HEMATOLOGIST	**Prof. Dr. Dominick Dytfeld** Department of Hematology and Bone Marrow Transplantation, University of Medical Sciences, Porznan, Co-founder and President of the Polish Myeloma Consortium	**Dr Sandra Bašić Kinda** Chair of Myeloma Working Group of KroHEM, Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia	**Prof. Dr. Oliver Karanfilski** University Clinic for Hematology
PATIENT ORGANISATION REPRESENTATIVE	**Barbara Leonardi** Member of Fundaja Carita Myeloma patient included in a CT	**Mira Armour** Member of Mijelom CR0	**Mirjana Babamova** Member of HEMA
HEALTH AUTHORITY REPRESENTATIVE	**Ewa Oldak** Director of th Department for Clinical Trials of Medicinal Products	Medicinal Products and Medical Device Department of the Ministry of Health No response	**Marija Trajculeski:** Pharmacist, responsible for approval marketing CT **Besnik Hamiti:** principal associated of pharma-economic and pharmaco-epidemiological advice department
CLINICAL RESEARCH ORGANISATION (CRO) REPRESENTATIVE	**Łukasz Więch** Associate Director Sites at Accelerated Enrollment Solutions	Two managers with experience in clinical trials in Croatia who have perspectives about other CEE countries	**Dr. Gjoko Todorovski** Clinical Monitoring Manager, Regional Manager, Comac Medical

CONTACT US

Myeloma Patients Europe AISBL
Avenue Louise 143/4
1050 Brussels - Belgium

info@mpeurope.org

www.mpeurope.org

@mpeurope

@MyelomaEurope

Myeloma Patients Europe

Myeloma Patients Europe